We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recent Advances in RSV Prevention: Strategies to Protect Infants from Severe Disease.
- Authors
Zentay, Zoltan; Faison, Giulia M.; Fu-Sheng Chou
- Abstract
RSV infections in infancy show a global prevalence with varying rates across different regions. While not significantly increasing perinatal risks such as low birth weight or preterm birth, RSV presents a substantial health burden. In infants, RSV is a leading cause of hospital admissions and mortality, especially in those under six months of age. The disease severity escalates with decreasing age, underscoring the need for effective prophylactic strategies. Advancements in the understanding of RSV biology have led to various vaccine approaches, including live-attenuated, vector-based, and subunit vaccines. Notable among these is Pfizer’s bivalent RSVpreF vaccine, which has shown promise in Phase 2 and Phase 3 trials, demonstrating significant efficacy in reducing severe RSV-associated illnesses in infants born to vaccinated mothers. Moreover, recent advancements in monoclonal antibody technologies have introduced nirsevimab, an anti-RSV monoclonal antibody with a long serum half-life, offering broader protection with a single administration and expanding prophylactic options for infants. In conclusion, the advent of maternal RSV vaccines and long-acting monoclonal antibodies marks a new era in RSV prophylaxis. While economic considerations remain outside this review's scope, they are crucial for policymaking. The evidence suggests the potential benefit of nirsevimab for prematurely born infants, irrespective of maternal vaccination status, offering comprehensive protection against severe RSV disease. This review emphasizes the evolving landscape of RSV prophylaxis and the need for ongoing research and policy adaptation.
- Subjects
PFIZER Inc.; LOW birth weight; RESPIRATORY syncytial virus infections; INFANTS; RESPIRATORY syncytial virus infection vaccines; CLINICAL trials
- Publication
Magyar Nőorvosok Lapja, 2024, Vol 87, Issue 2, p75
- ISSN
0025-021X
- Publication type
Article